Recruiting

Observational Study

Sponsor:

University Health Network, Toronto

Code:

NCT02964637

Conditions

Corticobasal Syndrome

Progressive Supranuclear Palsy

Behavioral Variant Frontotemporal Dementia

Semantic Dementia

Progressive Nonfluent Aphasia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

Observational Study

Study Details

Brief summary:

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

Conditions

Corticobasal Syndrome

Progressive Supranuclear Palsy

Behavioral Variant Frontotemporal Dementia

Semantic Dementia

Progressive Nonfluent Aphasia

Study ID

NCT02964637

Start date

Aug, 2015

Status verified date

Apr, 2019

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Participant must have a reliable study partner who can provide an independent evaluation of functioning.
  • Able to read, understand and speak English for neuropsychological testing.
  • All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and \[18F\]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND
  • Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28

Exclusion Criteria:

  • Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD
  • History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.
  • Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.
  • Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Progressive supranuclear palsy

Observational Study

Corticobasal syndrome

Observational Study

Behavoral variant FTD

Observational Study

Semantic variant PPA

Observational Study

Non-fluent variant PPA

Observational Study

FTD-motor neuron disease

Observational Study

Healthy controls

Observational Study

Interventions

Observational Study

Primary outcome measure

  • Structural and Functional Diffferences between the FTLD groups via MRI of the brain [ Time Frame: One time visit through study completion of 5 years ]
  • Differences between the FTLD groups via PET imaging of the brain [ Time Frame: One time visit through study completion of 5 years ]

Central Contacts and Locations

Central contacts

Cristina Salvo, BSc, MD

416-507-6880cristina.salvo@uhn.ca

Locations

Toronto Western Hospital, University Health Network

Recruiting

Toronto, Ontario, Canada, M5T 2S8

Contacts

Carmela Tartaglia, MD

416-603-5483carmela.tartaglia@uhn.ca

More Information

Sponsor

University Health Network, Toronto

Last update posted

Mar 30, 2025

Last verified

Apr, 2019

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University Health Network, Toronto on 2025-03-30.